阿德福韦酯联合微卡、乙肝疫苗治疗慢性乙型肝炎临床效果观察

Observation of clinical effect by adefovir dipivoxil combined with vaccae and hepatitis B vaccine in the treatment of chronic hepatitis B

目的观察阿德福韦酯联合微卡、乙肝疫苗治疗慢性乙型肝炎临床效果。方法 85例慢性乙型肝炎患者,按照治疗方法不同分为参照组(43例)和研究组(42例)。参照组患者采用阿德福韦酯片治疗,研究组患者在参照组治疗基础上联合微卡、乙肝疫苗治疗。比较两组治疗效果及安全性。结果研究组治疗总有效率为95.2%,高于参照组的76.7%,差异具有统计学意义(χ~2=5.9936,P=0.0143<0.05)。两组不良反应发生率比较差异无统计学意义(χ~2=1.0360,P=0.3087>0.05)。结论慢性乙型肝炎采用阿德福韦酯联合微卡、乙肝疫苗治疗效果显著,安全性高,具有积极的临床选择和推广价值。

Objective To observe clinical effect by adefovir dipivoxil combined with vaccae and hepatitis B vaccine in the treatment of chronic hepatitis B. Methods A total of 85 patients with chronic hepatitis B were divided by different treatment measures into control group（43 cases） and research group（42 cases）. The control group received adefovir dipivoxil tablets for treatment, and the research group received additional vaccae and hepatitis B vaccine to adefovir dipivoxil tablets for combined treatment. Curative effects and safety were compared between the two groups. Results The research group had higher total effective rate in treatment as 95.2% than 76.7% in the control group, and their difference had statistical significance（χ2=5.9936, P=0.0143〈0.05）. There was no statistically significant difference of incidence of adverse reactions between the two groups（χ2=1.0360, P=0.3087〉0.05）. Conclusion Combination of adefovir dipivoxil, vaccae and hepatitis B vaccine shows excellent curative effect and high safety in the treatment of chronic hepatitis B. This method contains positive value for clinical selection and promotion.